Observational Study "J-HERZ" Launched to Examine Real-World Use and Effectiveness of Lung Cancer Drug Zongertinib
Published
The Japan Lung Cancer Society and Boehringer Ingelheim Japan have announced that they will jointly conduct "J-HERZ," an observational study examining how zongertinib, a lung cancer treatment drug, is used and how effective it is in actual medical practice.
The study targets approximately 300 patients with non-small cell lung cancer harboring a HER2 gene mutation. The eligible patients are those whose cancer has metastasized or spread to surrounding tissues. The study will follow the progress of patients treated with zongertinib over a period of five years.
In clinical trials, the efficacy and safety of a drug are confirmed under predetermined conditions. In actual clinical practice, however, patients' conditions and treatment courses vary widely. For this reason, the observational study aims to clarify how zongertinib is used in everyday medical care and what effects it has.
Non-small cell lung cancer is the most common type of lung cancer. The information obtained from this study is expected to serve as a reference for future treatment.
Sources: Boehringer Ingelheim
More Japan news
- Toyota, Nissan and Honda to Hold Engineer Event in Fiscal 2026 Under the Theme of “AI”
- HTC NIPPON Promotes Business Use of the Smart Glasses "VIVE Eagle" as Sponsor of Remote Guidance App Exhibition
- Defense-Related ETF "GX Defense Tech" Publishes Stock Price Information; Detailed News Not Available
- U.S. Ambassador to South Korea Marks 100 Days in Office, Stresses the Importance of Protecting Trust Between South Korea and the United States
- South Korean National Assembly Passes Special Counsel Act to Investigate "Fabricated Indictments"
- Former Professor Embroiled in Stem Cell Paper Fabrication Scandal Acquires UAE Citizenship, Loses South Korean Nationality
- Foreign Minister Motegi Holds Talks with Foreign Ministers of France, Italy and the UK, Calls for Appropriate Response on EU Exclusion of Japanese-Made EVs from Preferential Treatment
- Health Drink Market in Japan Set to Grow, Driven by Aging Population and Health Consciousness